OMEGABIOL

С 1000 mg масло от диви , студеноводни риби , от които 800 mg Омега 3 мастни киселини. В последните има 400 mg Ейкозапентаенова киселина (ЕПК) и 300 mg Докозахексаенова киселина (ДХК) Допринася за нормалното функциониране на сърцето, мозъка и зрението. В кои случаи може да се използва Омега 3? Сърдечно-съдови заболявания и атеросклероза (за намаляване на нивата на триглицеридите и LDL холестерола, и поддържане на нормално кръвно налягане) Заболявания на ставите Деменция За по-добро функциониране на имунната система За по-добро зрение и при макулна дегенерация при възрастни За образуване на по-голямо количество сперматозоиди и подобряване на подвижността им При бременни, за правилно развитие на плода Какво представляват Омега 3 мастните киселини и за какво служат? Омега 3 мастните киселини са наречени есенциални, тъй като те не могат да се произвеждат от организма и трябва да се набавят с храната. Алфа-линоленовата киселина (АЛК) се открива в някои растения като: семена (лен, чиа), ядки (орехи) и масла (соя, рапица). В черния дроб AЛК се превръща в Докозахексаенова киселина (ДХК), след това тя в Ейкозапентаенова киселина (EПК). Последната е основен източник на простагландини от тип 3 ( ПГ3), с противовъзпалителни, антиалергични и съдоразширяващи свойства.     ДХК и ЕПК са в най-голяма концентрация в морските продукти и спомагат за правилното функциониране на сърцето, мозъка и очите.   Омега 3 имат различни въздействия, като някои механизми все още не са изяснени напълно: Те са универсалните съставки на биологичните мембрани на всички клетки в организма Осигуряват активността на протеините, които съдържат Използват се за покриване на енергийни нужди на организма. Омега 3 могат да се превърнат в АТФ в митохондриите или да се съхраняват в мастните клетки като триглицериди Имат невропротективни свойства и участват в много мозъчни и когнитивни функции като запаметяване, възприятие и концентрация Омега 3 са основни структурни съставки на централната нервна система и обуславят правилното функциониране на нервните клетки Участват в междуклетъчната комуникация, по-специално чрез процесите на невротрансмисия (миелинова обвивка) Те имат важно действие за регулиране на голям брой гени, чрез активиране на транскрипционни фактори, клетъчния растеж и диференциация   Защо е нужен допълнителен прием на ДХК и ЕПК? Учените установяват, че преобразуването на Омега 3 мастни киселини от предшественика им АЛК в клетката, не е много активно. Той се влияе много фактори като: възраст, пол, стрес или генетично предразположение. Клиничните изследвания  показват, че само от 2 до10% от консумираната АЛК се превръща в ЕПК или ДХК 1 . Следователно е от съществено значение да осигурим чрез храната, директни източници на ЕПК и ДХК за нашето тяло. Значителни количества ЕПК и ДХК има във всички мазни риби, които се хранят с водорасли и фитопланктон (сьомга, скумрия, сардини, херинга и др.), морски дарове, крил, рибени масла… От 2010 г. Френската агенция за контрол на храните,  препоръчва прием на ЕПК и ДХК от 500 mg на ден за възрастен. Данните обаче показват, че консумацията на АЛК в количества, достъпни чрез обичайната диета, не са достатъчни, за да задоволят нуждите на организма от Омега 3 (и по-специално от ДХК). Поради това е необходимо допълнителен прием на Омега-3 и по-специално на ЕПК и ДХК! СЗО издава следните препоръки за прием на Омега-3: ➢ АЛК: от 0,8 g до 1,1 g / ден ➢ ЕПК + ДХК: от 0,3 g до 0,5 g / ден     Защо избрахме норвежката фирма Epax? Гарантирана чистота и качество Epax е най-големият норвежки производител на Омега 3! Продуктите му се отличават с изключителна чистота и качество (трайност, проследимост и безопасност). Epax има над 170 години опит в областта на морската биология. Компанията е член на Глобалния консорциум на производителите на омега-3 (GOED). Но Хартата за качество на Epax далеч надхвърля нормите на GOED и действащите разпоредби. За премахване на различни замърсители и тежки метали от това масло, се използват патентовани процеси на молекулярна дестилация. Така се постигат несравними нива на чистота на маслото, 60 до 95% по-високо от настоящите Норвежката агенция по лекарствата, Европейската фармакопея и FDA! Маслото на Epax е без мирис и с нива на триглицериди от 90% ( 60% при конкурентите)!     Устойчив риболов Това масло се получава от малки, диви риби (сардини, аншоа, скумрия). Тези малки риби естествено съдържат много по-малко замърсители на околната среда, отколкото по-големите видове. Те се ловят в морето в съответствие с изискванията на екологично отговорния риболов и са сертифицирани от организацията „Friend of the Sea“ , за спазване на методите и устойчивостта на риболова. Освен че е сертифициран от „Friend of the Sеа“ , Epax е признат и от IFFO RS (Глобален стандарт за отговорно снабдяване). „Friend of the Sea“ е единствената програма за сертифициране на устойчив риболов, призната и контролирана в световен мащаб, като национален орган по акредитация. Гарантиран , нисък индекс TOTOX (показва степента на окисление) По дефиниция маслата, богати на полиненаситени мастни киселини, са податливи на окисляване. Това намалява хранителните им качества и влошава органолептичните характеристики. Получват се летливи молекули, които могат да усложнят храносмилането. Защитата на маслата срещу окислението започва от етапа на екстракция. Epax налага строги логистични спецификации за суровината: - Контролиране на температурите и нивата на кислород (     Висока бионаличност Благодарение на патента за естественото обогатяване на рибените масла с ЕПК и ДХК, се постига висока концентрация на Омега 3. Това позволява да се намали размерът на капсулите, като същевременно се запазват маслата в тяхната триглицеридна форма. Последната е най-често срещаната и води до по-добра бионаличност за организма!   Epax е компанията с най-много рецензирани, клинични изследвания ( над 100 на брой), свързани с Омега 3! Тези изследвания обхващат различни аспекти на медицината: кардиология, ревматология, неврология, акушерство, офталмология, имунология и др. Сърдечно-съдови заболявания von Schacky C, Angerer P, Kothny W. Et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann.Intern.Med. 1999;130:554-562 von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications.LIPIDS 2001;36:S99-S102 Lervang HH, Schmidt EB, Møller JM. Et al. The effect of low-dose supplementation with n-3 polyunsaturated fatty acids on some risk markers of coronary heart disease. Scand J Clin Lab Invest 1993;53:417-423 Markmann P, Lerche C, Nørtoft LL. A critical view on using fish-oil in prevention of ischaemical heart disease. Ugeskr Laeger 1992;154:2288-2292 Schmidt EB. n-3 fatty acids and the risk of coronary heart disease. Dan.Med.Bull 1997;44:1-22 Marckmann P, Bladbjerg EM, Jespersen J et al. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler.Thromb.Vasc.Biol. 1997;17:3384-3391 Rees D, Miles EA, Banerjee T, et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. American.journal of clinical.nutrition 2006;83:331-342 Cazzola R, Russo-Volpe S, Miles EA, et al. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 2007;193:159-167 Einvik G, Klemsdal TO, Sandvik L et al. A randomized clinical trial on n-3 PUFA supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Rehab 2010;17:588-592 Hjerkinn EM, Abdelnoor M, Breivik L et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention and Rehabilitation 2006;13:325-333 Dyerberg J, Eskesen DC, Andersen PW et al. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. European.journal of clinical.nutrition 2004;58:1062-1070 Dyerberg J, Christensen JH, Eskesen D et al. Trans, and n-3 polyunsaturated fatty acids and vascular function-A yin yang situation. Atherosclerosis.Supplements 2006;33-35 Schmidt EB, Varming K, Pedersen JO et al. Long-term supplementation with n-3 fatty acids. Scan J Clin Lab Invest 1992;52:229-236 Wu S-Y, Mayneris-Perxachs J, Lovegrove JA, Todd S, and Yaqoob P. Fish-oil supplementation alters numbers of circulating endothelial progenitor cells and microparticles independent of eNOS genotype. AJCN 2014 doi: 10.3945/ajcn.114.088880. Minihane AM, Khan S, Leigh-Firbank EC et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Atheriosclerosis, thrombosis, and vascular biology 2000;20:1990-1997 Nordøy A, Hatcher LF, Ullman DL et al. Individual effects of dietary saturated fatty acids and fish oil on plasma lipids and lipoproteins in men. Am J Clin Nutr 1993;57:634-639 Schmidt EB, Ernst E, Varming K et al. The effect of n-3 fatty acids on lipids and haemostasis in patients with Type IIa and Type IV hyperlipidemia. Thromb Haemostas 1989;62:797-801 Schmidt EB, Sørensen PJ, Pedersen JO et al. The effect of n-3 polyunsaturated fatty acids on lipids, haemostasis, neutrophil and monocyte chemotaxis in insulin-dependant diabetes mellitus. J Intern Med 1989;225 (suppl):201-206  Schmidt EB, Varming K, Ernst E et al. Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Tromb Haemostas 1990;63:1-5 Schmidt EB, Pedersen JO, Varming K et al. N-3 fatty acids and leucocyte chemotaxis. Effects in hyperlipidaemia and dose-response studies in healthy men. Arterosclerosis and Thrombosis 1991;11:429-435 Schmidt EB, Klausen IC, Kristensen SD et al. The effect of n-3 polyunsaturated fatty acids on Lp(a). Clin Chim Acta 1991;198:271-278 Schmidt EB, Varming K, Svaneborg N et al. N-3 polyunsaturated fatty acid supplementation in men with moderate and severe hypertriglyceridemia: a dose-response study. Ann Nutr Metab 1992;36:283-287 Schmidt EB, Lervang HH, Varming K et al. Long-term supplementation with n-3 fatty acids: effects on blood lipids, haemostasis and blood pressure. Scand J Clin Lab Invest 1992;52:221-228 Svaneborg N, Møller JM, Schmidt EB et al. The acute effects of a single very high dose of n-3 fatty acids on plasma lipids and lipoproteins in healthy subjects. Lipids 1994;29:145-147 Stark KD, Park EJ, Maines VA et al. Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 2000;72:389-394 Seljeflot I, Johansen O, Arnesen H et al. Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids. Thromb.Haemost. 1999;81:566-570 Lindman AS, Pedersen JI, Hjerkinn EM et al. The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis.and haemostasis 2004;6:1097-1104 Barstad RM, Roald HE, Petersen LB et al. Dietary supplementation of omega-3 fatty acids has no effect on acute collagen induced thrombus formation in flowing native blood. Blood Coagul Fibrinolysis. 1995;6:374-381 Flaten H, Høstmark AT, Kierulf P et al. Fish-oil concentrate: effects on variables related to cardiovascular disease. Am J Clin Nutr 1990;52:300-306 Freese R, Mutanen M. Alpha-linolenic acid and marine long-chain n-3 fatty acids only slightly differ in their effects on haemostatic factors in healthy subjects. Am J Clin Nutr 1997;66:591-598 Freese R, Mutanen M. Small effects of linseed oil or fish oil supplementation on postprandial changes in hemostatic factors. Thromb Res 1997;85(2):147152 Freese R. Dietary fatty acids and hemostasis. Effects of n-3 and n-6 fatty acids on platelet function and coagulation in healthy subjects. 1997;Uni Helsinki 75 Müllertz A, Hølmer G, Grøndahl-Hansen J et al. Increased concentration of plasminogen activator inhibitor type-1 in plasma after intake of fish oil. Fibrinolysis 1990;4(suppl 2):86-88 Christensen JH, Gustenhoff P, Korup E et al. n-3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial. Ugeskr.Laeger 1997;159:5526-5529 Christensen JH, Gustenhoff P, Korup E et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 1996;312:677-678 Christensen JH, Gustenhoff P, Ejlersen E et al. n-3 fatty acids and ventricular extrasystoles in patients with ventricular tachyarrhythmias. Nutrition Res 1995;15:1-8 Christensen JH, Gustenhoff P, Korup E et al. n-3 fatty acids and ventricular arrhythmias in post-myocardial infarction patients with a low ejection fraction 1995;10:107-114 Christensen JH, Christensen MS, Dyerberg J et al. Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 1999;70:331-337 Christensen JH, Aarøe J, Knudsen N et al. Heart rate variability and n-3 fatty acids in patients with chronic renal failure. Clin Neprol 1998;49:102-106 Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, Manohar LG, Morgan JG, Sparks PB. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: Reversal of tachycardia-mediated atrial cardiomyopathy with fish oils. Heart Rhythm 2011;8:643-649 Seljeflot I, Arnesen H, Brude IR et al. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur.J.Clin.Invest. 1998;28:629-635 Berstad P, Seljeflot I, Veierod MB et al. Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clinical.science 2003;105:13-20 Eid H, Arnesen H, Hjerkinn EM et al. Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. Nutrition & Metabolism 2006;3:4 Furenes EB, Seljeflot I, Solheim S et al. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and PAPP-A in men at high risk of coronary heart disease. SCLI 2008;68:177-184 Bonnema SJ, Jespersen LT, Marving J et al. Supplementation with olive oil rather than fish oil increases small arterial compliance in diabetic patients Diab Nutr & Metabol 1995;8:81-87 Hjerkinn EM, Seljeflot I, Ellingsen I et al. Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. American.journal of clinical.nutrition 2005;81:583-589 Christensen JH, Therkelsen K, Møller JM et al. n-3 fatty acids do not decrease plasma endothelin levels in healthy individuals. Scan J Clin Invest 1997;57:495-500 Fashing P, Ratheiser K, Waldhäusl W et al. Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance. Diabetes 1991;40:583-589 Fashing P, Rohac M, Liener K et al. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. Horm Metab Res 1996;28:230-236 Troseid M, Seljeflot I, Hjerkinn EM et al. Il-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome. Diab Care 2008;32:486-492 Kamolrat T, Gray SR, and Thivierge MC. Fish oil positively regulates anabolic signalling alongside an increase in whole-body gluconeogenesis in ageing skeletal muscle. Eur J Nutr 2013;52(2):647-657 Flachs P, Rossmeisl M, and Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol Res 2014;63(1): 93-118 Kopecky J, et al. Combined intervention with Pioglitazone and n-3 fatty acids in metformin-treated diabetic patients on postprandial lipid clearance and selected cytokines. Nutrition & Metabolism NUAM-D-15-00080R1 Razny,U., Kiec-Wilk,B., Polus,A., Goralska,J., Malczewska-Malec,M., Wnek,D., Zdzienicka,A., Gruca,A., Childs,C.E., Kapusta,M., Slowinska-Solnica,K., Calder,P.C., and Dembinska-Kiec,A. (2015) Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: A randomized placebo controlled trial, BBA clinical 4, 7-13. Bas JM, Caimari A, Rodriguez-Naranjo MI, Childs CE, Chavez CP, West AL, Miles EA, Arola L, Calder PC. Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n–3 polyunsaturated fatty acids in a randomized controlled trial. Am J Clin Nutr 2016;104:266-279 Razny Urszula, Beata Kiec-Wilk, Anna Polus, Joanna Goralska, Malgorzata Malczewska-Malec, Dominika Wnek, Anna Zdzienicka et al. 2015. Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: a randomized placebo controlled trial. BBA Clinical 2015;4:7–13 Clark,L.F., Thivierge,M.C., Kidd,C.A., McGeoch,S.C., Abraham,P., Pearson,D.W.M., Horgan,G.W., Holtrop,G., Thies,F., and Lobley,G.E. (2016) Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial, The British journal of nutrition 115, 75-86 Polus A, Zapala B, Razny U, Gielicz A, Kiec-Wilk B, Malczewska-Malec M, Sanak  M, Childs CE, Calder PC, Dembinska-Kiec A. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim Biophys Acta. 2016;1861(11):1746-1755 Rohith N. Thota, Shamasunder H. Acharya and Manohar L. Garg. Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial, Thota et al. Lipids in Health and Disease (2019) 18:31 https://doi.org/10.1186/s12944-019-0967-x   Ставни заболявания   Espersen GT, Grunnet N, Lervang HH et al.  Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids.  Clin Rheum 1992;11(3):393-395   Faarvang KL, Nielsen, Thomsen BS et al.  Fish oil and rheumatoid arthritis: a randomised double-blind study. Ugeskrift Laeger 1994;156:3495-3498   Hansen GVO, Nielsen L, Kluger E et al.  Nutritional status of Danish rheumatoid patients and effects of a diet adjusted in energy intake, fish-oil and antioxidants.  Scand J Rheumatol 1996;25:325-330   Nielsen GL, Faarvang BS, Thomsen BS et al.  The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis.  Eur J Clin Invest 1992;22:687-691   Volker DH, Fitzgerald P, Major G et al.  Efficacy of a fish-oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 2000;27:2343-2346   Sundstrom B, Stalnacke K, Hagfors L et al.  Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis.  Scandinavian journal of rheumatology. 2006;39:359-362   Деменция   Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T et al.  Omega-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial.  Archives of neurology 2006;63:1402-1408   Freund-Levi Y, Basun H, Cederholm T et al.  Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms.  Internat J Geriatric Psych 2008;23(2):161-169   Faxen-Irving G, Freund-Levi Y, Eriksdotter Jonhagen M, et al.  N-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease.  Journal Am Geriatric Soc 2009;57:11-17   Vedin I, Cederholm T, Freund Levi Y, et al.  Effects of docosahexaenoic acid–rich n3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.  Am J Clin Nutr 2008;87:1616 –22   Lai KL, Shahar S, Chin AV, et al.  Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 2013;225:605–612   Lai KL, Shahar S; Rajab N, et al.  The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case-control study.  Journal of nutritional biochemistry 2013; 24 (5):803-808   Faxen-Irving G, Freund-Levi Y,  Eriksdotter-Jonhagen M, et al.  Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n - 3 Fatty Acid Supplementation in Patients with Alzheimers Disease: The OmegAD Study.  Journal of Alzheimers disease 2013;36(1):1 - 6 Акушерство и гинекология   Olsen SF, Sørensen JD, Secher NJ et al.  A randomised controlled trial of effect of fish-oil supplementation on pregnancy duration.  Lancet 1992;339:1003-1007   Olsen SF, Sørensen JD, Secher NJ et al.  Fish-oil supplementation and pregnancy duration: a randomised controlled trial.  Ugeskr Laeger 1994;156:1302-1307   Olsen SF, Secher NJ, Tabor A et al.  Randomised clinical trial of fish oil supplementation in high risk pregnancies. Brit J Obstet Gynecol 2000;107:382-395   Salvig JD, Olsen SF, Secher NJ.  Effects of fish oil supplementation in late pregnancy on blood pressure: a randomised controlled trial.  Brit J Obstet Gynecol 1996;103:529-533   Sørensen JD, Olsen SF, Pedersen AK et al.  Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production.  Am J Obstet Gynecol 1993;168:915-922   Sørensen JD, Olsen SF, Secher NJ et al.  Effects of fish oil supplementation in late pregnancy on blood lipids, serum urate, coagulation and fibrinolysis: a randomised controlled study.  Fibrinolysis 1994;8:54-60   Vanhouwelingen AC, Sørensen JD, Hornstra G et al.  Essential fatty acid status in neonates after fish-oil supplementation during late pregnancy  Br J Nutr 1995;74:723-731   Olsen SF, Osterdal ML, Salvig JD et al  Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil.  European journal of clinical nutrition; 2007;61(8): 976-85   Freeman MP, Hibbeln JR, Wisner KL et al.  Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression.  Acta psychiatrica Scandinavica 2006;113:31-35   Klingler M, Blaschitz A, Campoy C et al.  The effect of docosahexaenoic acid and folic acid supplementation on placental apoptosis and proliferation.  British Journal of Nutrition 2006;96:182-190   Barque E, Krauss-Etschmann S, Campoy C et al.  Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins.  American Journal of Clinical Nutrition 2006;84:853-861   Shoji H, Franke C, Campoy C et al.  Effect of docosahexaenoic acid and eicosapentaenoic acid supplementation on oxidative stress levels during pregnancy.  Free Radical Research 2006;40:379-384   Имунология Mølvig J, Pociot F, Worsaae H et al.  Dietary supplementation with n-3 polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals.  Scand J Immunol 1991;34:399-410   Schmidt EB, Varming K, Møller JM et al.  No effect of a very low dose of n-3 fatty acids on monocyte function in healthy humans.  Scan J Lab Invest 1996;56:87-92   Toft AD, Thorn M, Ostrowski K et al.  N-3 polyunsaturated fatty acids do not affect cytokine response to strenous exercise.  J Appl Physiol 2000;89:2401-2406   Varming K, Schmidt EB, Svaneborg N et al.  The effect of n-3 fatty acids on neutrophil chemiluminiscience.  Scand J Clin Lab Invest 1995;55:47-52   Rees D, Miles EA, Banerjee T et al.  Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men.  Am J Clin Nutr 2006;83:331-342   Josep M del Bas, Antoni Caimari, Maria Isabel Rodriguez-Naranjo et al.  Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n–3 polyunsaturated fatty acids in a randomized controlled trial.  Am J Clin Nutr 2016;104:266–79   Williams EJ, Baines KJ, Smart JM, Gibson PG, Wood LG.  Rosuvastatin, Lycopene and Omega-3 fatty acids: A potential treatment for systemic inflammation in COPD; a pilot study.  J of Nutr & Intermediary Metabolism. 2016;5:86-95   Здравословно хранене   Schmidt EB, Moller JM, Svaneborg N et al.  Safety aspects of fish oils: experience with an n-3 concentrate of reesterified triglycerides.  Drug Invest 1994;7:215-220   Schmidt EB, Moller JM, Svaneborg N et al.  Prevention and treatment of vascular disease. Safety aspects of dietary n-3 fatty acids.  Springer Verlag 1995;18:195-206 Други   Bioavailability:  Dyerberg J, Madsen P, Møller JM et al. N-3 fatty acids in prevention and treatment in vascular disease. Springer Verlag 1995;20:201-217   Bioavailability:  Nordøy A, Barstad L, Connor WE et al. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr 1991;53:1185-1190   Bioavailability:  Dyerberg J, Madsen P, Møller JM. Bioavailability of n-3 fatty acid formulations. Springer Verlag 1995;20:217-226   Transplantation:  Hansen JM, Løkkegaard H, Hoy CE et al. No effect of dietary fish oil on renal hemodynamics, tubular function, and renal function reserve in long-term renal transplant recipients. J Am Soc Nephrol 1995;5:1434-1440   Transplantation:  Hansen JM, Hoy CE, Strandgaard. Fish oil and cyclosporin A induced renal hypoperfusion in kidney-transplanted patients. Nephrology Dialysis Transplantation 1995;10:1745-1750   Physical performance:  Raastad T, Høstmark AT, Strømme SB. Omega-3 fatty acid supplementation does not improve maximal aerobic power, anaerobic threshold and running performance in well-trained soccer players. Scand J Med Sci Sports 1997;7:25-31   Digestion:  Riber C, Højgaard L, Madsen JL et al. Gallbladder emptying and cholecystokinin response to fish oil and trioleate ingestion. Digestion 1996;57(3):161-164   Weight reduction:  Kunnesova M, Srbova L, Hlavaty P et al. Praha omega-3 weight reduction study. ECO 2008; abstract   Infection:  Abu-Zeid YA, Hansen HS, Jakobsen PH et al. No effect of human serum and erythrocytes enriched in n-3 fatty acids by oral intake on plasmodium falciparum bloodstage parasites in vitro. Eur J Clin Nutr 1993;47:431-436   Depression:  Voggt A, Berger M, Obermeier M, Löw A, Seemueller F, Riedel M, Moeller HJ, Zimmermann R, Kirchberg F, Von Schacky C, Severus E. Heart rate variability and Omega-3 Index in euthymic patients with bipolar disorders. Eur Psychiatry  2015:30(2):228-232   Analysis:  Sjövall,P., Rossmeisl,M., Hanrieder,J., Kuda,O., Kopecky,J., and Bryhn,M. Dietary uptake of omega-3 fatty acids in mouse tissue studied by time-of-flight secondary ion mass spectrometry (TOF-SIMS), Analytical and bioanalytical chemistry 2015;407:5101-5111.   Depression:  Parletta N, Zarnowiecki D, Cho J, Wilson A, Bogomolova S, Villani A.  A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). Nutritional Neuroscience 2017;1411320   Psychotic Disorders:  McGorry PD, Nelson B, Markulev C.  Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders; The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry 2017;74(1):19-27   Psychotic Disorders:  Amminger GP, Schafer MR, Schlogelhofer M, Clier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna Omega-3 study. Nature communications 2015;6:7934   Eye Health:  McDonald MB, Sheha H, Tighe S, Janik SB, Bowden FW, Chokshi AR, Singer MA, Nanda S, Qazi MA, Dierker D, Shupe AT, McMurren BJ. Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study. Clin Ophthalmol. 2018 Apr 9;12:677-681 Опаковка: 60 капсули Производител: Ineldea Santé Naturalle, 06510 Carros, Франция